Skip to main content
. 2020 Nov 27;12(11):976–992. doi: 10.4254/wjh.v12.i11.976

Figure 2.

Figure 2

Inhibition of non-structural protein 4a-non-structural protein 3 protease domain by commercial inhibitors. A: VX-950; B: Danoprevir; C: Asunaprevir; and D: BILN 2061 and determination of inhibition constant (IC50).